Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| cannabinoid receptors agonists | 5177 | 140608-64-6 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
a murine monoclonal antibody to the CD3 antigen of human T cells which functions as an immunosuppressant
|
| Dose | Unit | Route |
|---|---|---|
| 5 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 14, 1992 | FDA | ORTHO BIOTECH |
None
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Post transplant lymphoproliferative disorder | 79.05 | 72.68 | 16 | 291 | 15597 | 110573395 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L04AG01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Monoclonal antibodies |
| FDA PE | N0000175550 | Decreased Immunologic Activity |
| FDA MoA | N0000175617 | CD3-directed Antibody Interactions |
| FDA MoA | N0000175619 | CD3 Receptor Antagonists |
| FDA EPC | N0000175620 | CD3 Blocker Immunosuppressant |
| MeSH PA | D007155 | Immunologic Factors |
| MeSH PA | D007166 | Immunosuppressive Agents |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Renal transplant rejection | indication | 236570004 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Surface antigen | ANTIBODY BINDING | UNKNOWN | IUPHAR |
| ID | Source |
|---|---|
| JGA39ICE2V | UNII |
| 4018561 | VANDF |
| C0085379 | UMLSCUI |
| CHEBI:749554 | CHEBI |
| CHEMBL1201608 | ChEMBL_ID |
| D05092 | KEGG_DRUG |
| DB00075 | DRUGBANK_ID |
| D016853 | MESH_DESCRIPTOR_UI |
| 6281 | INN_ID |
| 6889 | IUPHAR_LIGAND_ID |
| 109137000 | SNOMEDCT_US |
| 412251003 | SNOMEDCT_US |
| 3838 | MMSL |
| 5140 | MMSL |
| d03118 | MMSL |
| 003421 | NDDF |
| 227302 | RXNORM |
None